Details of the Drug Combination

General Information of Drug Combination (ID: DCQ8G66)

Drug Combination Name
Haloperidol SCH 420814
Indication
Disease Entry Status REF
Akathisia, Drug-Induced Phase 1 [1]
Component Drugs Haloperidol   DM96SE0 SCH 420814   DMMWCZS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Haloperidol
Disease Entry ICD 11 Status REF
Delirium N.A. Approved [2]
Nausea MD90 Approved [2]
Psychotic disorder 6A20-6A25 Approved [2]
Schizophrenia 6A20 Approved [3]
Vomiting MD90 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Tourette syndrome 8A05.00 Investigative [2]
Haloperidol Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [9]
HUMAN opioid receptor sigma 1 (OPRS1) TTTPE1L SGMR1_HUMAN Modulator [10]
HUMAN sigma intracellular receptor 2 (TMEM97) TTIS0R2 SGMR2_HUMAN Modulator [10]
------------------------------------------------------------------------------------
Haloperidol Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Haloperidol Interacts with 9 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [13]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [13]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [12]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [15]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [13]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [13]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DME(s)
Haloperidol Interacts with 129 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Affects Response To Substance [17]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [18]
D(1A) dopamine receptor (DRD1) OTLZPBT7 DRD1_HUMAN Affects Activity [19]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Affects Activity [19]
Brain-derived neurotrophic factor (BDNF) OTLGH7EW BDNF_HUMAN Increases Expression [20]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Affects Binding [21]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases ADR [22]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases ADR [22]
G protein-activated inward rectifier potassium channel 1 (KCNJ3) OTHQG16J KCNJ3_HUMAN Increases ADR [22]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Decreases Expression [18]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Expression [18]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [23]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [23]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [23]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [23]
Lathosterol oxidase (SC5D) OT41KMW4 SC5D_HUMAN Increases Expression [24]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Increases Expression [24]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Increases Expression [6]
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Increases Expression [6]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [6]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Increases Expression [6]
Transgelin (TAGLN) OTAEZ0KP TAGL_HUMAN Decreases Expression [6]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [6]
Lysophospholipase D GDPD3 (GDPD3) OTOHM9QM GDPD3_HUMAN Increases Expression [6]
Fibronectin type III domain-containing protein 4 (FNDC4) OTOQK0WK FNDC4_HUMAN Increases Expression [6]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [6]
AP-3 complex subunit beta-1 (AP3B1) OTYTIH5Q AP3B1_HUMAN Increases Expression [7]
Importin subunit alpha-3 (KPNA4) OTP0EX18 IMA3_HUMAN Increases Expression [7]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2) OT8L6EGI BCAT2_HUMAN Decreases Expression [7]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [25]
Period circadian protein homolog 1 (PER1) OTVQF3WX PER1_HUMAN Increases Expression [26]
Kinesin heavy chain isoform 5C (KIF5C) OT35570Y KIF5C_HUMAN Decreases Expression [7]
Copine-3 (CPNE3) OTCR3WG2 CPNE3_HUMAN Decreases Expression [7]
CCR4-NOT transcription complex subunit 3 (CNOT3) OT4D5Z9L CNOT3_HUMAN Decreases Expression [7]
Pyridoxal phosphate homeostasis protein (PLPBP) OT9DZ8P6 PLPHP_HUMAN Increases Expression [7]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Increases Expression [27]
Fatty acid-binding protein, heart (FABP3) OT562DA1 FABPH_HUMAN Increases Expression [7]
Prothymosin alpha (PTMA) OT2W4T1M PTMA_HUMAN Increases Expression [7]
Corticoliberin (CRH) OT2MOC4T CRF_HUMAN Decreases Expression [28]
Profilin-1 (PFN1) OTHTGA1H PROF1_HUMAN Increases Expression [7]
Signal recognition particle receptor subunit alpha (SRPRA) OT5NMYTY SRPRA_HUMAN Decreases Expression [7]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Decreases Expression [7]
Glycogen phosphorylase, muscle form (PYGM) OTWLVWTV PYGM_HUMAN Decreases Expression [7]
Histidine--tRNA ligase, cytoplasmic (HARS1) OTHOEOTS HARS1_HUMAN Increases Expression [7]
Plastin-3 (PLS3) OTYBM4PK PLST_HUMAN Decreases Expression [7]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Decreases Expression [7]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4) OTJZG0LD GLUT4_HUMAN Increases Expression [29]
Ezrin (EZR) OTHBPF1Z EZRI_HUMAN Decreases Expression [7]
V-type proton ATPase subunit B, kidney isoform (ATP6V1B1) OT8FQ7MN VATB1_HUMAN Decreases Expression [7]
Probable ATP-dependent RNA helicase DDX5 (DDX5) OTLS124U DDX5_HUMAN Decreases Expression [7]
Vascular endothelial growth factor receptor 1 (FLT1) OTT0OGYS VGFR1_HUMAN Decreases Expression [7]
Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PCMT1) OTGYVSGU PIMT_HUMAN Decreases Expression [7]
Cofilin-1 (CFL1) OTT6D5MH COF1_HUMAN Increases Expression [7]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) OTJC60Q7 THIL_HUMAN Decreases Expression [7]
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Affects Binding [30]
General transcription factor IIE subunit 1 (GTF2E1) OTAG9V0I T2EA_HUMAN Decreases Expression [7]
Stress-induced-phosphoprotein 1 (STIP1) OT7TXLOX STIP1_HUMAN Decreases Expression [7]
Catenin alpha-1 (CTNNA1) OTFC725Z CTNA1_HUMAN Decreases Expression [7]
Radixin (RDX) OTNSYUN6 RADI_HUMAN Decreases Expression [7]
Vascular endothelial growth factor receptor 2 (KDR) OT15797V VGFR2_HUMAN Increases Expression [7]
Transgelin-2 (TAGLN2) OTUXZGDQ TAGL2_HUMAN Decreases Expression [7]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA) OTIOLNHE LICH_HUMAN Increases Expression [7]
Pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1) OTNBHULA PACR_HUMAN Affects Expression [8]
Small ribosomal subunit protein eS27 (RPS27) OTFXKY7P RS27_HUMAN Increases Expression [7]
Cell surface glycoprotein MUC18 (MCAM) OTT8XKGE MUC18_HUMAN Increases Expression [7]
Vesicle-fusing ATPase (NSF) OTKRJ2ZT NSF_HUMAN Decreases Expression [7]
Serine--tRNA ligase, cytoplasmic (SARS1) OTFKXQ1O SYSC_HUMAN Decreases Expression [7]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL) OT50L4XB ACADV_HUMAN Decreases Expression [7]
Peroxisomal multifunctional enzyme type 2 (HSD17B4) OT8733D7 DHB4_HUMAN Decreases Expression [7]
Delta-1-pyrroline-5-carboxylate synthase (ALDH18A1) OT6W40XU P5CS_HUMAN Decreases Expression [7]
Heterogeneous nuclear ribonucleoprotein K (HNRNPK) OTNPRM8U HNRPK_HUMAN Decreases Expression [7]
Small ribosomal subunit protein uS9 (RPS16) OTVGZOB5 RS16_HUMAN Decreases Expression [7]
Large ribosomal subunit protein eL30 (RPL30) OTLQVY1Z RL30_HUMAN Increases Expression [7]
Microtubule-associated protein 1A (MAP1A) OTHO8K43 MAP1A_HUMAN Decreases Expression [7]
Large ribosomal subunit protein eL19 (RPL19) OT33LM66 RL19_HUMAN Decreases Expression [7]
Transcriptional activator protein Pur-alpha (PURA) OT975ELW PURA_HUMAN Increases Expression [7]
Protein Dr1 (DR1) OTR081M4 NC2B_HUMAN Decreases Expression [7]
Synaptic vesicular amine transporter (SLC18A2) OTUOMMM6 VMAT2_HUMAN Affects Binding [31]
Mitochondrial-processing peptidase subunit alpha (PMPCA) OT5X1G9Q MPPA_HUMAN Increases Expression [7]
Aspartyl/asparaginyl beta-hydroxylase (ASPH) OT3KGDEE ASPH_HUMAN Increases Expression [7]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [32]
Translation initiation factor eIF2B subunit epsilon (EIF2B5) OTV3R4RB EI2BE_HUMAN Increases Expression [7]
Transcription intermediary factor 1-beta (TRIM28) OTE38OBF TIF1B_HUMAN Decreases Expression [7]
Condensin complex subunit 2 (NCAPH) OTXOS97C CND2_HUMAN Decreases Expression [7]
Inorganic pyrophosphatase (PPA1) OTHZK1QB IPYR_HUMAN Increases Expression [7]
Reticulocalbin-1 (RCN1) OT3JBGAG RCN1_HUMAN Decreases Expression [7]
Splicing factor 3B subunit 4 (SF3B4) OTGB9OR9 SF3B4_HUMAN Decreases Expression [7]
Disks large homolog 2 (DLG2) OTQ3BD8U DLG2_HUMAN Increases Expression [7]
Striated muscle preferentially expressed protein kinase (SPEG) OTQXWJR4 SPEG_HUMAN Increases Expression [7]
Cryptochrome-1 (CRY1) OTTGAJT0 CRY1_HUMAN Decreases Expression [26]
Histone H2A type 2-C (H2AC20) OTEIVLM1 H2A2C_HUMAN Increases Expression [7]
Tau-tubulin kinase 1 (TTBK1) OTYW316L TTBK1_HUMAN Increases Expression [7]
Coiled-coil domain-containing protein 121 (CCDC121) OTWZ4FTT CC121_HUMAN Increases Expression [7]
Nucleoporin p54 (NUP54) OTHOIRMG NUP54_HUMAN Decreases Expression [7]
Retinol dehydrogenase 11 (RDH11) OTIND43N RDH11_HUMAN Decreases Expression [7]
Dynein axonemal heavy chain 3 (DNAH3) OTD2JOKM DYH3_HUMAN Increases Expression [7]
Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 (DHX38) OTBVB3W5 PRP16_HUMAN Decreases Expression [7]
Small ribosomal subunit protein mS31 (MRPS31) OTB0OBWK RT31_HUMAN Increases Expression [7]
AP-2 complex subunit mu (AP2M1) OTQCOSFN AP2M1_HUMAN Increases Expression [7]
Probable ATP-dependent RNA helicase DDX27 (DDX27) OT64NCZ6 DDX27_HUMAN Increases Expression [7]
PDZ and LIM domain protein 5 (PDLIM5) OTLQVV22 PDLI5_HUMAN Decreases Expression [7]
Kremen protein 1 (KREMEN1) OTGJFSAC KREM1_HUMAN Increases Expression [7]
KH domain-containing RNA-binding protein QKI (QKI) OTTAUGLB QKI_HUMAN Increases Expression [33]
Transcriptional regulator protein Pur-beta (PURB) OTCDDKYB PURB_HUMAN Decreases Expression [7]
Melanin-concentrating hormone receptor 1 (MCHR1) OTT57EOE MCHR1_HUMAN Affects Binding [34]
Transmembrane 9 superfamily member 2 (TM9SF2) OTA0C202 TM9S2_HUMAN Decreases Expression [7]
COP9 signalosome complex subunit 4 (COPS4) OTNK2KS1 CSN4_HUMAN Decreases Expression [7]
Histone H2A.J (H2AJ) OTVA4XTW H2AJ_HUMAN Increases Expression [7]
MKI67 FHA domain-interacting nucleolar phosphoprotein (NIFK) OT20GHN3 MK67I_HUMAN Decreases Expression [7]
ATP-dependent DNA/RNA helicase DHX36 (DHX36) OT8IGL9Y DHX36_HUMAN Decreases Expression [7]
tRNA:m(4)X modification enzyme TRM13 homolog (TRMT13) OT2H0MCE TRM13_HUMAN Decreases Expression [7]
Tropomodulin-3 (TMOD3) OTQPNSTH TMOD3_HUMAN Decreases Expression [7]
Endoplasmic reticulum aminopeptidase 1 (ERAP1) OT72S99B ERAP1_HUMAN Decreases Expression [7]
Ribosome-binding protein 1 (RRBP1) OT4ZTPTM RRBP1_HUMAN Decreases Expression [7]
DnaJ homolog subfamily B member 11 (DNAJB11) OTDDK2SY DJB11_HUMAN Increases Expression [7]
Translocation protein SEC63 homolog (SEC63) OT1ICPMK SEC63_HUMAN Increases Expression [7]
Cysteine and histidine-rich domain-containing protein 1 (CHORDC1) OT3W6F1U CHRD1_HUMAN Increases Expression [7]
Unconventional myosin-Vb (MYO5B) OTCKL3W3 MYO5B_HUMAN Decreases Expression [7]
Pre-mRNA-processing factor 19 (PRPF19) OTQ1STV3 PRP19_HUMAN Increases Expression [7]
E3 ubiquitin-protein ligase PDZRN3 (PDZRN3) OTQ891OS PZRN3_HUMAN Decreases Expression [7]
DNA-binding protein SATB2 (SATB2) OT2W80XC SATB2_HUMAN Decreases Expression [7]
TRPM8 channel-associated factor 1 (TCAF1) OTSQQ37P TCAF1_HUMAN Decreases Expression [7]
Talin-2 (TLN2) OT10QQBC TLN2_HUMAN Decreases Expression [7]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Increases ADR [22]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Increases ADR [22]
Dysbindin (DTNBP1) OT9UQT2S DTBP1_HUMAN Increases Response To Substance [35]
NADH-ubiquinone oxidoreductase chain 1 (ND1) OTCLGIXV NU1M_HUMAN Increases ADR [22]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases ADR [22]
Synaptosomal-associated protein 25 (SNAP25) OTUIQ81Q SNP25_HUMAN Affects Response To Substance [36]
------------------------------------------------------------------------------------
⏷ Show the Full List of 129 DOT(s)
Indication(s) of SCH 420814
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [5]
SCH 420814 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosine A2a receptor (ADORA2A) TTM2AOE AA2AR_HUMAN Antagonist [37]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00693472) Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
2 Haloperidol FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 86).
4 Sigma-1Rs are upregulated via PERK/eIF2/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5614).
6 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
7 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
8 Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors. Neurochem Res. 2017 Apr;42(4):943-952. doi: 10.1007/s11064-016-2127-2. Epub 2016 Nov 30.
9 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
10 A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
11 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
12 Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
13 In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
14 Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
15 Drug Interactions Flockhart Table
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004 Dec;24(6):656-60. doi: 10.1097/01.jcp.0000145340.53417.ca.
18 Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox. Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):81-5.
19 Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
20 The differential effects of neuroleptic drugs and PACAP on the expression of BDNF mRNA and protein in a human glioblastoma cell line. Acta Neurobiol Exp (Wars). 2017;77(3):205-213.
21 The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
22 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
23 Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 2005;5(5):298-304.
24 Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
25 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
26 Haloperidol, but not olanzapine, may affect expression of PER1 and CRY1 genes in human glioblastoma cell line. Biol Rhythm Res. 2016 Nov 1;47(6):865-871. doi: 10.1080/09291016.2016.1202379. Epub 2016 Jul 1.
27 The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000 Sep;22(9):1085-96. doi: 10.1016/S0149-2918(00)80086-7.
28 Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology. 2006 Apr;31(4):853-65. doi: 10.1038/sj.npp.1300911.
29 Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells. J Psychiatr Res. 2006 Jun;40(4):374-9. doi: 10.1016/j.jpsychires.2005.04.016. Epub 2005 Jul 5.
30 Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
31 Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994 Mar;22(1-4):219-26. doi: 10.1016/0169-328x(94)90050-7.
32 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
33 Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells. BMC Pharmacol. 2009 Mar 31;9:6. doi: 10.1186/1471-2210-9-6.
34 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
35 The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics. 2009 Jun;19(6):437-46. doi: 10.1097/FPC.0b013e32832b9cfc.
36 The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett. 2005 May 6;379(2):81-9. doi: 10.1016/j.neulet.2004.12.037. Epub 2005 Jan 26.
37 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.